News

b

b

Current News in Drug Discovery

RSS Nature Reviews Drug Discovery
  • RIPK3 inhibitor prevents lung damage in severe influenza infection April 24, 2024
    Nature Reviews Drug Discovery, Published online: 24 April 2024; doi:10.1038/d41573-024-00072-wRIPK3 inhibitor prevents lung damage in severe influenza infection
    Joseph Willson
  • mRNA therapy shows promise for metabolic disorder April 23, 2024
    Nature Reviews Drug Discovery, Published online: 23 April 2024; doi:10.1038/d41573-024-00071-xmRNA therapy shows promise for metabolic disorder
    Sarah Crunkhorn
  • RNA-editing drugs advance into clinical trials April 18, 2024
    Nature Reviews Drug Discovery, Published online: 18 April 2024; doi:10.1038/d41573-024-00070-yADAR-based editors that can change the mRNA code offer new opportunities in both rare genetic diseases and common complex ones.
    Asher Mullard
  • Three-step cures for autoimmune diseases? April 17, 2024
    Nature Reviews Drug Discovery, Published online: 17 April 2024; doi:10.1038/d41573-024-00069-5Robert Plenge, head of Research at Bristol Myers Squibb, discusses his vision of sequential immunotherapy for autoimmune diseases — including multiple sclerosis.
    Asher Mullard
  • The antibody–drug conjugate landscape April 16, 2024
    Nature Reviews Drug Discovery, Published online: 16 April 2024; doi:10.1038/d41573-024-00064-wThe antibody–drug conjugate landscape
    Patrick Flynn
  • Targeting immunogenic cell stress and death for cancer therapy April 15, 2024
    Nature Reviews Drug Discovery, Published online: 15 April 2024; doi:10.1038/s41573-024-00920-9Immunogenic cell death (ICD) is crucial for the elicitation of anticancer immune responses by therapy, but the successful development of ICD-inducing treatments is hindered by various obstacles. This Review provides an overview of the core mechanisms of ICD, discusses obstacles to the development of novel ICD […]
    Lorenzo Galluzzi
  • FDA new drug approvals in Q1 2024 April 12, 2024
    Nature Reviews Drug Discovery, Published online: 12 April 2024; doi:10.1038/d41573-024-00063-xFDA new drug approvals in Q1 2024
    Paul Verdin
  • FDA approves first complement factor D inhibitor April 11, 2024
    Nature Reviews Drug Discovery, Published online: 11 April 2024; doi:10.1038/d41573-024-00067-7FDA approves first complement factor D inhibitor
    Asher Mullard

Vitreon America™ Launches Botanicopeia™ Database and Federal Government Services at NIH Festival+

 BETHESDA, MD, September 17, 2016 − Vitreon America, Inc. participated this week in the National Institute of Health (NIH) Intramural Research Program’s 30th Annual NIH Research Festival which was held September 15-16, 2016 at the NIH Bethesda, Maryland campus.

The Festival included plenary sessions, symposia, exhibits, poster sessions and tours designed to encourage sharing and learning about the exciting research taking place on NIH campus.

Vitreon America was selected by the Technical Sales Association (TSA) which sponsors the Research Festival Exhibit, to launch its state-of-the-art Phytochemical and Ethnobotanical database subscription services, Botanicopeia.

Attending on behalf of Vitreon America
were Michael Megginson, VP of Business Development (left) and Jorgen Sandberg,
CEO (right).

Vitreon America was pleased to see the interest from the NIH Institutions to utilize the Botanicopeia database subscriptions with many NIH researchers expressing interest in considering the Vitreon America Botanical Research Analytic services as well to optimize the Botanicopeia database.

Based on the NIH researchers feedback, Vitreon America has established a Botanicopeia database subscription service agreement and subscription service with botanical research analytic services through Marshall Communications Corporation, www.marshallcomm.com.

Vitreon America services are available through Marshall Communications Corporation (VOSB) on NIH’s Information Technology Acquisition and Assessment Center’s (NITAAC)- Government-wide Acquisition Contract (GWAC) vehicle. [Prime Contract Holder #HHSN316201500063W]

Vitreon America was established with the goal of commercializing their Botanicopeia database and botanical research analytic services for development of botanicals and phytochemicals in the creation of new medicinal products by Vitreon America Clients.

To find out more about our Services please contact us for assistance at 1-888-214-2584 or at info@vitreonamerica.com

About Vitreon America™

Vitreon AmericaTM was formed with the goal of disseminating their BotanicopeiaTM database to encourage the increased use of botanicals and phytochemicals in the creation of new medicines.

Contact Vitreon America, Inc.

Vitreon America Botanical Research Center @ Hopkins Johns Hopkins University

MCC 9601 Medical Center Drive, Suite 221
Rockville, Maryland 20850

+1-888-214-2584

j.shaver@advasur.com